The medtech sector experienced 706 funding deals encompassing $5.8 billion in venture capital investments in 2016, down from 676 deals of $6.42 billion in 2015. By contrast, 2014 boasted 800 funding deals comprising $6.8 billion.
To address dwindling investment in medical devices, companies should engage in strategic partnerships and co-development initiatives, according to the report. In 2016, the plurality of co-development activity in the medtech sector — 45 percent — related to in-vitro diagnostics.
Other co-development partners hailed from health IT (19 percent), diabetes care device (5 percent) and cardiovascular device (3 percent) sectors, among others.
To access the full report, click here.
More articles on supply chain:
Philips to suspend some defibrillator manufacturing in US: 5 things to know
FDA approves record number of generics in FY 17
Consumers view drugs as less risky when more side effects are listed in ads
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
